LAS VEGAS — September 23, 2026
DelveInsight Business Research, LLP published its latest Myotonic Dystrophy Market Insights report, outlining the current treatment landscape, patient population, emerging therapies and market outlook across the seven major markets (7MM) through 2036. According to DelveInsight’s estimates, the myotonic dystrophy treatment market was valued at approximately $236 million in the 7MM in 2025, while the diagnosed population was estimated at approximately 110,000 individuals. The report identifies increasing disease awareness, wider adoption of genetic testing, advances in RNA-targeted and other precision therapies, and expanding clinical research activity as factors that could influence future market development.
Emerging Therapies Expand Myotonic Dystrophy Pipeline
The myotonic dystrophy pipeline includes a range of investigational approaches aimed at addressing disease mechanisms in addition to symptomatic management. DelveInsight identifies candidates including tideglusib (AMO-02) from AMO Pharma, delpacibart etedesiran (del-desiran) from Novartis and Avidity Biosciences, zeleciment basivarsen (z-basivarsen/DYNE-101) from Dyne Therapeutics, PGN-EDODM1 from PepGen, VX-670 from Vertex Pharmaceuticals, SRP-1003 from Sarepta Therapeutics, ATX-01 from ARTHEx Biotech, JUV-161 from Juvena Therapeutics and MDL-202 from Modalis Therapeutics. Tideglusib is an oral GSK3β inhibitor being investigated in congenital DM1, while del-desiran is an antibody oligonucleotide conjugate designed to reduce disease-associated DMPK mRNA. The report also highlights RNA-targeted small-molecule approaches in preclinical development.
Diagnosis and Research Activity Shape Market Outlook
DelveInsight identifies improved disease recognition and access to genetic testing as important factors influencing the diagnosed patient population and treatment landscape. Greater availability of specialized neuromuscular services and genetic counseling may support earlier diagnosis and family screening, while increased clinical research is expanding the number of potential disease-modifying approaches. The report notes that myotonic dystrophy currently has no approved therapy that cures the disease or definitively slows its underlying progression, leaving treatment largely focused on symptom management, including therapies for myotonia and associated complications. DelveInsight also highlights recent development activity, including planned one-year data presentations for Dyne’s z-basivarsen, AMO Pharma’s regulatory discussions concerning a registrational study of AMO-02, PepGen’s clinical development of PGN-EDODM1 and FDA Fast Track Designation for ARTHEx’s ATX-01
Advertisement
Myotonic Dystrophy Market Forecast Extends to 2036
The report provides epidemiological and commercial forecasts from 2022 through 2036 across the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. DelveInsight estimates that the United States represented the largest myotonic dystrophy treatment market among the 7MM in 2025, with approximately 57,000 diagnosed prevalent cases. The report evaluates diagnosed prevalence, disease subtypes, age-specific populations, associated comorbidities, treatment patterns, market access and reimbursement considerations. While the outlook anticipates that successful development of disease-modifying therapies could expand treatment options and market demand, clinical development outcomes, regulatory decisions, diagnosis rates and reimbursement conditions remain important uncertainties. The report therefore provides a market and pipeline assessment of an evolving therapeutic landscape rather than a forecast of individual drug approvals or clinical success.
Source :DelveInsight press release
